Group One Trading’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-100
| Closed | -$11.4K | – | 8798 |
|
|
2025
Q2 | $11.4K | Buy |
+100
| New | +$10.7K | ﹤0.01% | 6635 |
|
|
2024
Q2 | – | Sell |
-5,000
| Closed | -$366K | – | 7141 |
|
|
2024
Q1 | $366K | Hold |
5,000
| – | – | ﹤0.01% | 3034 |
|
|
2023
Q4 | $357K | Sell |
5,000
-12,100
| -71% | -$714K | ﹤0.01% | 3353 |
|
|
2023
Q3 | $1.02M | Buy |
17,100
+14,600
| +584% | +$961K | ﹤0.01% | 2246 |
|
|
2023
Q2 | $180K | Buy |
+2,500
| New | +$188K | ﹤0.01% | 4051 |
|
|
2022
Q1 | – | Sell |
-3,687
| Closed | -$355K | – | 8376 |
|
|
2021
Q4 | $355K | Sell |
3,687
-160
| -4% | -$14.8K | ﹤0.01% | 4498 |
|
|
2021
Q3 | $334K | Buy |
3,847
+1,282
| +50% | +$99.2K | ﹤0.01% | 4635 |
|
|
2021
Q2 | $210K | Sell |
2,565
-194,604
| -99% | -$16.2M | ﹤0.01% | 5205 |
|
|
2021
Q1 | $18.8M | Buy |
197,169
+105,798
| +116% | +$10M | 0.03% | 569 |
|
|
2020
Q4 | $5.67M | Buy |
91,371
+2,244
| +3% | +$128K | 0.01% | 1180 |
|
|
2020
Q3 | $5.3M | Sell |
89,127
-37,029
| -29% | -$2.53M | 0.02% | 883 |
|
|
2020
Q2 | $8.8M | Buy |
126,156
+93,294
| +284% | +$5.91M | 0.04% | 508 |
|
|
2020
Q1 | $1.49M | Sell |
32,862
-29,655
| -47% | -$1.68M | 0.01% | 1228 |
|
|
2019
Q4 | $4.07M | Buy |
62,517
+1,603
| +3% | +$107K | 0.03% | 796 |
|
|
2019
Q3 | $3.78M | Buy |
60,914
+40,716
| +202% | +$2.56M | 0.03% | 754 |
|
|
2019
Q2 | $1.44M | Sell |
20,198
-34,785
| -63% | -$2.56M | 0.01% | 1342 |
|
|
2019
Q1 | $4.31M | Buy |
54,983
+32,381
| +143% | +$2.45M | 0.05% | 510 |
|
|
2018
Q4 | $1.91M | Buy |
22,602
+16,350
| +262% | +$1.74M | 0.02% | 1067 |
|
|
2018
Q3 | $1.07M | Buy |
6,252
+6,092
| +3,808% | +$918K | 0.01% | 1653 |
|
|
2018
Q2 | $21K | Buy |
+160
| New | +$17.9K | ﹤0.01% | 4347 |
|
|
2018
Q1 | – | Sell |
-321
| Closed | -$27K | – | 5082 |
|
|
2017
Q4 | $27K | Hold |
321
| – | – | ﹤0.01% | 4037 |
|
|
2017
Q3 | $27K | Sell |
321
-27,732
| -99% | -$2.2M | ﹤0.01% | 3931 |
|
|
2017
Q2 | $2.13M | Sell |
28,053
-166,551
| -86% | -$11.7M | 0.02% | 924 |
|
|
2017
Q1 | $12.8M | Buy |
194,604
+92,974
| +91% | +$6.12M | 0.15% | 140 |
|
|
2016
Q4 | $6.44M | Buy |
101,630
+101,309
| +31,560% | +$6.39M | 0.06% | 345 |
|
|
2016
Q3 | $20K | Sell |
321
-8,976
| -97% | -$659K | ﹤0.01% | 3775 |
|
|
2016
Q2 | $692K | Sell |
9,297
-8,015
| -46% | -$595K | 0.01% | 1497 |
|
|
2016
Q1 | $1.16M | Buy |
17,312
+8,656
| +100% | +$526K | 0.02% | 1079 |
|
|
2015
Q4 | $585K | Buy |
8,656
+962
| +13% | +$59.4K | 0.01% | 1696 |
|
|
2015
Q3 | $411K | Sell |
7,694
-16,191
| -68% | -$982K | 0.01% | 1933 |
|
|
2015
Q2 | $1.5M | Buy |
23,885
+7,053
| +42% | +$385K | 0.02% | 926 |
|
|
2015
Q1 | $810K | Buy |
16,832
+13,305
| +377% | +$510K | 0.01% | 1243 |
|
|
2014
Q4 | $117K | Sell |
3,527
-4,648
| -57% | -$151K | ﹤0.01% | 2724 |
|
|
2014
Q3 | $240K | Sell |
8,175
-5,130
| -39% | -$170K | ﹤0.01% | 2235 |
|
|
2014
Q2 | $517K | Sell |
13,305
-1,603
| -11% | -$65K | 0.01% | 1624 |
|
|
2014
Q1 | $626K | Buy |
14,908
+14,587
| +4,544% | +$608K | 0.01% | 1466 |
|
|
2013
Q4 | $11K | Sell |
321
-37,510
| -99% | -$1.22M | ﹤0.01% | 4540 |
|
|
2013
Q3 | $1.02M | Sell |
37,831
-25,648
| -40% | -$722K | 0.02% | 1005 |
|
|
2013
Q2 | $1.48M | Buy |
+63,479
| New | +$1.14M | 0.04% | 583 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Group One Trading's LGND Position: Q1 2026 in Review
Group One Trading reduced its Ligand Pharmaceuticals (LGND) stake by 43% in Q1 2026, selling an estimated $254K and leaving 1,669 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #3711.
Group One Trading first reported a position in LGND in Q3 2013 and has held it in 21 quarters since. The position peaked at $3.99M in Q1 2017. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Group One Trading held 1,669 shares of Ligand Pharmaceuticals worth $333K as of Q1 2026.
- Group One Trading sold 1,284 Ligand Pharmaceuticals shares in Q1 2026, an estimated $254K.
- Ligand Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3711 holding.
- Group One Trading first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 21 quarters since.
- Group One Trading's Ligand Pharmaceuticals position peaked at $3.99M in Q1 2017.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.